Catherine M. Szyman - 14 Jan 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Critical Care
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
14 Jan 2022
Net transactions value
-$977,663
Form type
4
Filing time
14 Jan 2022, 18:16:37 UTC
Previous filing
17 Dec 2021
Next filing
18 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $217,600 +10,000 +36% $21.76 37,415 14 Jan 2022 Direct F1
transaction EW Common Stock Sale $133,934 -1,116 -3% $120.01 36,299 14 Jan 2022 Direct F1, F2
transaction EW Common Stock Sale $1,061,329 -8,884 -24% $119.47 27,415 14 Jan 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -10,000 -11% $0.000000 83,400 14 Jan 2022 Common Stock 10,000 $21.76 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 4, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $119.960 to $120.085. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $118.960 to $119.950. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.